Evidence map›Paper›PMID 41757189›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Contribution of dominant and recessive model effects to the genetic architecture of Idiopathic Pulmonary Fibrosis.

Tamara Hernandez-Beeftink, Lauren J Donoghue, Abril Izquierdo, Samuel T Moss, Daniel Chin, Beatriz Guillen-Guio, Konain Fatima Bhatti, Simon Biddie, Nick Shrine, Richard Packer and 43 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

53 authors.

Tamara Hernandez-BeeftinkDivision of Public Health and Epidemiology, School of Medical Sciences, University of Leicester, Leicester, UK.
Lauren J DonoghueGenentech, California, USA.
Abril IzquierdoDivision of Public Health and Epidemiology, School of Medical Sciences, University of Leicester, Leicester, UK.
Samuel T MossDivision of Public Health and Epidemiology, School of Medical Sciences, University of Leicester, Leicester, UK.
Daniel ChinDivision of Public Health and Epidemiology, School of Medical Sciences, University of Leicester, Leicester, UK.
Beatriz Guillen-GuioDivision of Public Health and Epidemiology, School of Medical Sciences, University of Leicester, Leicester, UK.
Konain Fatima BhattiImperial College London, London, UK.
Simon BiddieMRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Nick ShrineDivision of Public Health and Epidemiology, School of Medical Sciences, University of Leicester, Leicester, UK.
Richard PackerDivision of Public Health and Epidemiology, School of Medical Sciences, University of Leicester, Leicester, UK.
Ayodeji AdegunsoyeUniversity of Chicago, Chicago, USA.
Helen L BoothUniversity College London Hospitals, London, UK.
CleanUP-IPF Investigators of the Pulmonary Trials Cooperative
William A FahyGlaxoSmithKline, London, UK.
Tasha E FingerlinNational Jewish Health, Colorado, USA.
Ian P HallCentre for Respiratory Research, NIHR Nottingham Biomedical Research Centre, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.
Simon P HartUniversity of Hull, Hull, UK.
Mike R HillUniversity of Oxford, Oxford, UK.
Nik HiraniUniversity of Edinburgh, Edinburgh, UK.
Naftali KaminskiYale School of Medicine, Connecticut, USA.
Elena Lopez-JimenezImperial College London, London, UK.
Jose Miguel Lorenzo-SalazarGenomics Division, Instituto Tecnologico y de Energias Renovables, Santa Cruz de Tenerife, Spain.
Shwu-Fan MaUniversity of Virginia, Virginia, USA.
Robin J McAnultyUniversity College London, London, UK.
Mark I McCarthyGenentech, California, USA.
Amy D StockwellGenentech, California, USA.
Toby M MaherNIHR Imperial Biomedical Research Unit, National Heart and Lung Institute, Imperial College London, London, UK.
Ann B MillarUniversity of Bristol, Bristol, UK.
Philip L MolyneauxNational Institute for Health Research Respiratory Clinical Research Facility, Royal Brompton Hospital, London, UK.
Maria Molina-MolinaServei de Pneumologia, Laboratori de Pneumologia Experimental, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona, Spain.
Vidya NavaratnamDepartment of Respiratory Medicine, Sir Charles Gardiner Hospital, Perth, Australia.
Margaret NeighborsGenentech, California, USA.
Justin M OldhamUniversity of Michigan, Michigan, USA.
Helen ParfreyRoyal Papworth Hospital NHS Foundation Trust, Cambridge, UK.
Gauri SainiUniversity of Nottingham, Nottingham, UK.
Ian SayersCentre for Respiratory Research, NIHR Nottingham Biomedical Research Centre, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.
X Rebecca ShengGenentech, California, USA.
Mary E StrekUniversity of Chicago, Chicago, USA.
Iain StewartNIHR Imperial Biomedical Research Unit, National Heart and Lung Institute, Imperial College London, London, UK.
Martin D TobinDivision of Public Health and Epidemiology, School of Medical Sciences, University of Leicester, Leicester, UK.
Moira Kb WhyteUniversity of Edinburgh, Edinburgh, UK.
Yingze ZhangUniversity of Pittsburgh, Pittsburgh, USA.
Fernando J MartinezUMass Chan Medical School, Massachusetts, USA.
Brian L YaspanGenentech, California, USA.
Carl J ReynoldsImperial College, London, UK.
David A SchwartzUniversity of Colorado Medicine, Colorado, USA.
Carlos FloresGenomics Division, Instituto Tecnologico y de Energias Renovables, Santa Cruz de Tenerife, Spain.
Imre NothUniversity of Virginia, Virginia, USA.
Alison E JohnImperial College London, London, UK.
R Gisli JenkinsNIHR Imperial Biomedical Research Unit, National Heart and Lung Institute, Imperial College London, London, UK.
Richard J AllenDivision of Public Health and Epidemiology, School of Medical Sciences, University of Leicester, Leicester, UK.
Olivia C LeavyDivision of Public Health and Epidemiology, School of Medical Sciences, University of Leicester, Leicester, UK.
Louise V WainDivision of Public Health and Epidemiology, School of Medical Sciences, University of Leicester, Leicester, UK.

Funding

Targeting early events in MUC5B-driven lung injury and fibrosisP01HL162607 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI David Albert Schwartz · 2023 to 2026
$12.4M
Preclinical Pulmonary Fibrosis, an opportune rare disease cohortUH3HL151865 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2022 to 2025
$4.3M
Molecular Determinants of Usual Interstitial Pneumonia (UIP)R01HL158668 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI David Albert Schwartz, Ivana V Yang · 2022 to 2026
$3.5M
Genes and Transcripts that Interact with MUC5B in Pulmonary FibrosisR01HL149836 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI CLOUTHIER, DAVID E., SCHWARTZ, DAVID ALBERT · 2020 to 2023
$3.0M
Proteomic Profiling of Idiopathic Pulmonary Fibrosis Progression TrajectoryR01HL169166 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2023 to 2026
$2.7M
The role of quantitative CT and radiomic biomarkers for precision medicine in pulmonary fibrosisR01HL171918 · NHLBI · UNIVERSITY OF VIRGINIA · PI Imre Noth · 2024 to 2026
$2.2M
Prognostic Biomarker Development in Progressive Fibrosing Interstitial Lung DiseaseR01HL166290 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2024 to 2026
$2.2M
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUG3HL145266 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARTINEZ, FERNANDO J, NOTH, IMRE · 2019 to 2019
$977k
Elucidating the Genomic Determinants of Outcomes in Idiopathic Pulmonary FibrosisK23HL138190 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI OLDHAM, JUSTIN M · 2017 to 2021
$914k
Improving Pulmonary Fibrosis Classification with Genomics Informed Phenotypic ClustersK23HL146942 · NHLBI · UNIVERSITY OF CHICAGO · PI ADEGUNSOYE, AYODEJI · 2020 to 2024
$810k
Derivation and validation of a clinical-molecular signature to predict fibrotic progression and treatment response in patients with autoimmune interstitial lung diseaseR56HL158935 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI OLDHAM, JUSTIN M · 2021 to 2021
$400k
BLRD VA I01 BX005295NHLBI NIH HHS K23 HL138190NHLBI NIH HHS K23 HL146942NHLBI NIH HHS P01 HL162607NHLBI NIH HHS R01 HL149836NHLBI NIH HHS R01 HL158668NHLBI NIH HHS R01 HL166290NHLBI NIH HHS R01 HL169166NHLBI NIH HHS R01 HL171918NHLBI NIH HHS R56 HL158935NHLBI NIH HHS UG3 HL145266NHLBI NIH HHS UH3 HL151865Wellcome Trust
6 · The paper itself

Abstract

Rationale: Idiopathic pulmonary fibrosis (IPF) is a rare, chronic, progressive lung disease with high mortality and few treatment options. Using an additive genetic model, genome-wide association studies (GWAS) have identified multiple risk loci highlighting new genes and pathways of interest. Since IPF risk could also be influenced by non-additive effects, we hypothesised that association analyses using alternative genetic models may provide additional mechanistic insight. Objectives: To perform GWAS of IPF susceptibility to detect associations where the underlying effects are consistent with recessive or dominant genetic models. Methods: We performed GWAS of IPF susceptibility, with logistic regression assuming dominant or recessive genetic models, including 5,159 IPF cases, from clinically-curated sources, and 27,459 controls. We functionally annotated independent signals and performed variant-to-gene mapping, applying fine-mapping to define potentially causal variants and genes. We assessed differential expression levels of genes of interest in publicly available single cell RNAseq data and in primary cells derived from IPF donors and controls. Main Results: We identified five genome-wide significant signals, under a recessive model, that had not been reported previously. These included exonic variants in the cell-cycle gene Polyamine-Modulated Factor 1 ( Conclusions: Using alternative genetic models in IPF susceptibility GWAS identified new signals and genes, providing new insights into IPF pathogenesis and potential future therapies.

Indexed as

DominantGeneticsIdiopathic pulmonary fibrosisNon-additiveRecessiveSusceptibility GWAS

Identifiers

PMID41757189
PMCPMC12934843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.